Effectiveness of DNA-recombinant anti-hepatitis B vaccines in blood donors
Author Information
Author(s): Emil Kupek, Denise E. R. de Souza, Andrea Petry
Primary Institution: National Perinatal Epidemiology Unit, University of Oxford
Hypothesis
The study aims to evaluate the effectiveness of DNA-recombinant anti-HBV vaccines among blood donors in an endemic area in Brazil.
Conclusion
The results showed very high effectiveness of DNA-recombinant anti-HBV vaccines in blood donors.
Supporting Evidence
- The vaccinated cohort had zero incidences of hepatitis B, while the non-vaccinated cohort had 2.33 incidences per 1000 person-years.
- The study estimated that 429 vaccinated individuals are needed to prevent one HBV infection.
- The study followed 1411 blood donors over an average of 3.17 years.
Takeaway
Vaccinating blood donors against hepatitis B is very effective, helping to keep people safe from the virus.
Methodology
A double cohort study comparing vaccinated and unvaccinated blood donors over a period of 3.17 person-years.
Potential Biases
Selection bias may arise due to differences in health attitudes among blood donors.
Limitations
Potential residual confounding factors and underestimation of true HBV incidence due to testing limitations.
Participant Demographics
Repeat blood donors aged 18-65 from JoaƧaba, Brazil.
Statistical Information
Confidence Interval
95% CI from 30.1% to 100%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website